IQVIA, a global leader in clinical research services, commercial insights, and healthcare intelligence, announced a long-term strategic collaboration with Boehringer Ingelheim. The pharmaceutical company has selected IQVIA’s Data-as-a-Service platform, DaaS+, to drive its global commercial data harmonization and transformation initiative. This partnership is designed to accelerate Boehringer Ingelheim’s ability to scale commercial data products and analytics across multiple therapeutic areas and regional teams by leveraging an industry-leading global data model.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
Justin Gale, Global Head of Data Excellence at Boehringer Ingelheim, explained that integrating their global commercial data into a unified platform through IQVIA’s DaaS+ will streamline operations, enable advanced analytics, and support innovative use cases. He emphasized that the platform will help the company generate actionable insights and improve data-driven decision-making across its global business.
The collaboration aims to enhance both new product launches and the performance of existing markets by providing harmonized data for all market, brand, and franchise reporting across 59 countries. Boehringer Ingelheim will benefit from consistent product mastering, simplified data management, and direct access to IQVIA’s datasets, creating a more efficient workflow and stronger analytical capabilities.
Health Technology Insights: Adagio Medical Adds Executives to Boost ULTC Launch
Tom Baker, Senior Vice President of Global Data, Technologies, and Advisory Services at IQVIA, said the partnership will help Boehringer Ingelheim establish a robust global data foundation. He added that this will accelerate AI-powered analytics initiatives and allow faster, more informed business decisions across the organization.
Through this collaboration, IQVIA and Boehringer Ingelheim aim to set a new standard in commercial data management by combining harmonized global data with cutting-edge technology, empowering the pharmaceutical company to make smarter, faster, and more strategic decisions worldwide.
Health Technology Insights: ACCO Brands to Acquire EPOS
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
